Where is Noveo located?

Noveo is headquartered in Hong Kong, China.

Where does Noveo rank among its competitors?

Noveo ranks 148th amongst 122 active competitors, of which 25 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was ChromaCode, which secured $3.85M in Jan, 2025.

Who are the top competitors of Noveo?

Noveo's top competitors include Molbio Diagnostics, Biocartis and NeuMoDx. Among them, ChromaCode secured the most recent funding round in January, 2025.

Noveo - 2026 Company Profile & Competitors

Noveo is a deadpooled company based in Hong Kong (China), founded in 2015. It operates as a Developer of molecular diagnostic tests for oral and dental care. The company has 122 active competitors, including 25 funded and 25 that have exited. Its top competitors include companies like Molbio Diagnostics, Biocartis and NeuMoDx.

Company Details

Developer of molecular diagnostic tests for oral and dental care. It has developed a number of proprietary qPCR-based, multiparametric tests to assess and identify bacterial strains and risks associated with periodontal disease, evaluate the risk of dental caries, a saliva-based screening test for oral cancer, and tests for microbiological assessment of oral unit water. Noveo has also developed Dentalfreeze, a face-mask containing cold pouches for post-operative cryotherapy.

Key Metrics

Founded Year

2015

Location

Hong Kong, China

Stage

Deadpooled

Ranked

148^th among 162 competitors

Similar Companies

Molbio Diagnostics & 50 more

View Noveo's full profile

Noveo has not raised any funding rounds yet.

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Noveo include Molbio Diagnostics, Biocartis and NeuMoDx. Here is the list of Top 10 competitors of Noveo, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Molbio Diagnostics 2000, Salcete (India), Series C	Developer of point-of-care molecular diagnostic platform for infectious disease detection	$124M	Motilal Oswal, Temasek & 36 others	71/100
2nd	Biocartis 2007, Mechelen (Belgium), Public	Developer of molecular assays for the detection of various diseases	$305M	Johnson & Johnson Innovation – JJDC, Advent Life Sciences ... & 18 others	58/100
3rd	NeuMoDx 2012, Ann Arbor (United States), Acquired	Developer of a platform for low cost molecular testing	$66M	Arboretum Ventures, Wolverine Venture Fund ... & 3 others	58/100
4th	ChromaCode 2012, Carlsbad (United States), Series C	Digital molecular biology analytics for disease management	$95M	Northpond Ventures, New Enterprise Associates ... & 9 others	55/100
5th	DermTech 1996, San Diego (United States), Acquired	Provider of adhesive patch biopsy for skin cancer diagnostics	$24.4M	RTW Investments, Van Herk Groep & 3 others	54/100
6th	Biofire Diagnostics 1990, Salt Lake City (United States), Acquired	Provider of molecular diagnostic solutions for the detection of genetic conditions	$84M	Founders Fund, Athyrium Capital Management ... & 8 others	54/100
7th	QuantuMDx Group 2008, Newcastle Upon Tyne (United Kingdom), Series D	Manufacturer of molecular diagnostic platforms and assays for infectious diseases	$57.3M	Adjuvo, WG Partners & 3 others	49/100
8th	Quantalife 2008, Pleasanton (United States), Acquired	Life science research and clinical diagnostics solutions provider, powering possibilities	$28.7M	Paladin Capital, Vital Venture Capital & 3 others	48/100
9th	Co-Dx 2013, Salt Lake City (United States), Public	Provider of genomics-based information and solutions for transplant patients	$1.1M	NIH, SALSS	48/100
10th	SpeeDx 2009, Sydney (Australia), Series C	Provider of qPCR-based molecular diagnostics platform	$78M	Northpond Ventures, Platinum & 9 others	46/100
148th	Noveo 2015, Hong Kong (China), Deadpooled	Developer of molecular diagnostic tests for oral and dental care	-	-	15/100